[1]陈湘磊,蔡媛华,李景岗,等.基于SEER数据库的原发腮腺B细胞非霍奇金淋巴瘤分析[J].医学信息,2023,36(03):32-38.[doi:10.3969/j.issn.1006-1959.2023.03.008]
　CHEN Xiang-lei,CAI Yuan-hua,LI Jing-gang,et al.Analysis of Primary Parotid B-cell Non-Hodgkin’s Lymphoma Based on SEER Database[J].Journal of Medical Information,2023,36(03):32-38.[doi:10.3969/j.issn.1006-1959.2023.03.008]
点击复制

基于SEER数据库的原发腮腺B细胞非霍奇金淋巴瘤分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年03期
页码:
32-38
栏目:
医学数据科学
出版日期:
2023-02-01

文章信息/Info

Title:
Analysis of Primary Parotid B-cell Non-Hodgkin’s Lymphoma Based on SEER Database
文章编号:
1006-1959（2023）03-0032-07
作者:
陈湘磊; 蔡媛华; 李景岗; 等
（1.潍坊市益都中心医院血液科，山东 青州 262500；2.福建医科大学附属协和医院血液科，福建 福州 350001；3.福建医科大学医学技术与工程学院输血教研室，福建 福州 350001）
Author(s):
CHEN Xiang-lei; CAI Yuan-hua; LI Jing-gang; et al.
(1.Department of Hematology,Weifang Yidu Central Hospital,Qingzhou 262500,Shandong,China;2.Department of Hematology,Fujian Medical University Union Hospital,Fuzhou 350001,Fujian,China;3.Department of Blood Transfusion Medicine,School of Medical Technology and Engineering,Fujian Medical University,Fuzhou 350001,Fujian,China)
关键词:
原发腮腺淋巴瘤; 非霍奇金淋巴瘤; 总生存时间
Keywords:
Primary parotid lymphoma; Non-Hodgkin’s lymphoma; Total survival time
分类号:
R733.71
DOI:
10.3969/j.issn.1006-1959.2023.03.008
文献标志码:
A
摘要:
目的 利用SEER数据库总结原发腮腺淋巴瘤相关的人口学特征、临床特点及预后相关因子。方法 本研究纳入1987-2016年美国SEER数据库登记的原发腮腺B细胞非霍奇金淋巴瘤（NHL）病例。采用倾向评分匹配降低基线水平的混杂因子；K-M曲线进行单因素生存分析；Cox回归模型进行多因素分析；竞争风险回归模型进行原发腮腺淋巴瘤相关的生存分析。结果 共纳入1443例原发腮腺B细胞NHL，经2∶1倾向评分匹配后1170例患者纳入下一步分析，且多因素Cox回归分析显示，年龄与组织学类型是独立的OS预测因素。原发腮腺惰性B细胞NHL中＜50、50~59、60~69、70~79及≥80年龄段患者的中位OS分别为275、241、216、121及51个月（P＜0.05），组织学类型为MZL、FL及CLL/SLL患者的OS分别为195、180及78个月（P＜0.05），且1年及5年生存率分别为97.32%及85.02%。原发腮腺侵袭性B细胞NHL中＜50、50~59、60~69、70~79及≥80年龄段患者的中位OS分别为121、203、185、74及12.5个月（P＜0.05），且1年及5年生存率分别为84.92%及62.81%。共有546例死亡病例，最常见的死亡原因为NHL，其次为心脏病。竞争风险回归分析表明，年龄、组织学类型、Ann Arbor分期、诊断时间影响原发腮腺惰性B细胞NHL特异性死亡；年龄影响原发腮腺侵袭性B细胞NHL特异性死亡。结论 原发腮腺B细胞淋巴瘤主要的组织学亚型是MZL，组织学亚型和年龄与原发腮腺B细胞NHL预后密切相关。
Abstract:
Objective To summarize the demographic characteristics, clinical characteristics and prognostic factors of primary parotid lymphoma by SEER database.Methods Primary parotid B-cell non-Hodgkin’s lymphoma (NHL) cases registered in the US SEER database from 1987 to 2016 were included. Propensity score matching was used to reduce the confounding factors at the baseline level. K-M curve was used for single factor survival analysis. Cox regression model was used for multivariate analysis. The survival analysis of primary parotid lymphoma was performed by competitive risk regression model.Results A total of 1443 patients with primary parotid B-cell NHL were included, and 1170 patients were included in the next analysis after 2∶1 propensity score matching. Multivariate Cox regression analysis showed that age and histological type were independent predictors of OS. The median OS of patients aged <50,50-59,60-69,70-79 and ≥80 years in primary parotid indolent B-cell NHL was 275,241,216,121 and 51 months, respectively (P<0.05); the OS of patients with histological types of MZL, FL and CLL/SLL was 195,180 and 78 months, respectively (P<0.05); and the 1-year and 5-year survival rates were 97.32% and 85.02%, respectively. The median OS of patients with age<50,50-59,60-69,70-79, and ≥80 years in primary parotid aggressive B-cell NHL was 121,203,185,74, and 12.5 months, respectively (P<0.05), and the 1-year and 5-year survival rates were 84.92% and 62.81%, respectively. There were 546 death cases, the most common cause of death was NHL, followed by heart disease. Competitive risk regression analysis showed that age, histological type, Ann Arbor stage and diagnosis time affected the specific death of primary indolent B-cell NHL in parotid gland. Age affects the specific death of primary parotid aggressive B-cell NHL.Conclusion The main histological subtype of primary parotid B-cell lymphoma is MZL. The histological subtype and age are closely related to the prognosis of primary parotid B-cell NHL.

参考文献/References:

[1]Fatima S,Badri RNM,Siddiqui WA,et al.Primary salivary gland lymphomas: A case series[J].Libyan Journal of Medical Sciences,2020,4(4):192.[2]Aishwarya JG,Nair S,Patil CN,et al.Peripheral T Cell Lymphoma of Parotid Gland: A Diagnostic Challenge[J].Indian J Otolaryngol Head Neck Surg,2019,71(Suppl 1):533-536.[3]Ko K,Bhatia KS,Ai Q,et al.Imaging of head and neck mucosa-associated lymphoid tissue lymphoma (MALToma)[J].Cancer Imaging,2021,21(1):10.[4]Jamal B.Treatment of Parotid Non-Hodgkin Lymphoma: A Meta-Analysis[J].J Glob Oncol,2018,4:1-6.[5]Ozdamar OI,Acar GO,Karaca S,et al.Primary T-Cell Lymphoma of the Parotid Gland[J].J Coll Physicians Surg Pak,2022,32(3):392-394.[6]Austin PC,Latouche A,Fine JP.A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model[J].Stat Med,2020,39(2):103-113.[7]Austin PC,Steyerberg EW,Putter H.Fine-Gray subdistribution hazard models to simultaneously estimate the absolute risk of different event types: Cumulative total failure probability may exceed 1[J].Stat Med,2021,40(19):4200-4212.[8]Iversen L,Eriksen P,Andreasen S,et al.Lymphoma of the Sublingual Gland: Clinical,Morphological,Histopathological,and Genetic Characterization[J].Front Surg,2020,7:581105.[9]Wang J,Li R,Wang Q,et al.The clinicopathological features of parotid lymphoma[J].Int J Clin Exp Pathol,2020,13(8):2050-2057.[10]Feinstein AJ,Ciarleglio MM,Cong X,et al.Parotid gland lymphoma: prognostic analysis of 2140 patients[J].Laryngoscope,2013,123(5):1199-1203.[11]Walewski J,Paszkiewicz-Kozik E,Michalski W,et al.First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4[J].Br J Haematol,2020,188(6):898-906.[12]Gupta A,Lee JA,Nguyen SA,et al.Primary diffuse large B-cell lymphoma of the major salivary glands: Increasing incidence and survival[J].Am J Otolaryngol,2021,42(3):102938.[13]Sousou T,Friedberg J.Rituximab in indolent lymphomas[J].Semin Hematol,2010,47(2):133-142.[14]Tariq A,Aziz MT,Mehmood Y,et al.Clinical Response to CHOP vs.R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas[J].Asian Pac J Cancer Prev,2018,19(5):1181-1184.[15]Kirtane K,Lee SJ.Racial and ethnic disparities in hematologic malignancies[J].Blood,2017,130(15):1699-1705.[16]Wei Y,Wei X,Huang W,et al.Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma[J].Int J Hematol,2020,111(5):681-685.[17]Zapater E,Bagán JV,Carbonell F,et al.Malignant lymphoma of the head and neck[J].Oral Dis,2010,16(2):119-128.

相似文献/References:

[1]李云霞,赵 玲,赵明利,等.奈达铂联合吉西他滨阻滞非霍奇金淋巴瘤细胞周期促进细胞凋亡的作用研究[J].医学信息,2022,35(08):61.[doi:10.3969/j.issn.1006-1959.2022.08.015]
　LI Yun-xia,ZHAO Ling,ZHAO Ming-li,et al.Effect of Nedaplatin Combined with Gemcitabine on Cell Cycle Arrest and Apoptosis in Non-Hodgkin Lymphoma[J].Journal of Medical Information,2022,35(03):61.[doi:10.3969/j.issn.1006-1959.2022.08.015]

更新日期/Last Update: 1900-01-01